Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030472 · ClinicalTrials.gov registry record · Phase 2
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00030472: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00030472 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030472, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-12 |
| Phase | Phase 2 |
Why NCT00030472 stopped before completion
NCT00030472 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00030472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00030472 about?
NCT00030472 is a clinical study titled "Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.
What is the current status of trial NCT00030472?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-12.
What interventions are being tested in trial NCT00030472?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00030472?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia